Goldman Sachs initiated coverage of Oric Pharmaceuticals (ORIC) with an Early Stage Biotech rating. Oric is a clinical stage biotechnology company with a pipeline of oncology candidates focused on addressing resistance in cancer, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORIC:
- Buy Rating for Oric Pharmaceuticals: Promising Developments and Enozertinib’s Potential in NSCLC Treatment
- Oric Pharmaceuticals initiated with an Outperform at Evercore ISI
- Promising Potential of Oric Pharmaceuticals’ ORIC-944 in Prostate Cancer Market Drives Buy Rating
- Oric Pharmaceuticals price target raised to $20 from $17 at JPMorgan
- Oric Pharmaceuticals initiated with a Peer Perform at Wolfe Research